Atossa Therapeutics rides strong momentum in 2Q to clinical advancements and corporate expansionProactive Investors • 08/14/23
Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/14/23
Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023GlobeNewsWire • 08/08/23
Atossa Therapeutics gets green light to open enrollment for Phase 2 breast cancer trial in CanadaProactive Investors • 07/20/23
Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in CanadaGlobeNewsWire • 07/20/23
50% Of Women Have Elevated Breast Density, Which Significantly Decreases the Effectiveness of Mammography - Atossa Therapeutics Is Looking To Ensure Earlier, Accurate DiagnosisAccesswire • 07/12/23
Atossa Therapeutics provides update on Phase 2 breast density trial enrollmentProactive Investors • 07/10/23
Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical TrialGlobeNewsWire • 07/10/23
Atossa Therapeutics strikes sponsored research deal with Weill Cornell Medicine for triple negative breast cancerProactive Investors • 07/06/23
Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast CancerGlobeNewsWire • 07/06/23
Atossa Therapeutics hits 30% enrollment for (Z)-Endoxifen arm of ongoing I-SPY 2 clinical trialProactive Investors • 06/28/23
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical TrialPRNewsWire • 06/28/23
Pharmaceutical M&A thriving as global dealmaking struggles to stay healthyProactive Investors • 06/22/23
Atossa to Participate in Fireside Chat at Healthcare Virtual Conference Presented by Maxim Group LLCGlobeNewsWire • 06/14/23
Atossa Therapeutics is looking for a step-change in breast cancer therapyProactive Investors • 06/14/23
Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast CancerGlobeNewsWire • 06/12/23